| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
NNOX Stock Overview
Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source.
Nano-X Imaging Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.38 |
| 52 Week High | US$34.50 |
| 52 Week Low | US$8.23 |
| Beta | 0 |
| 1 Month Change | 7.01% |
| 3 Month Change | 4.32% |
| 1 Year Change | -58.48% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -52.17% |
Recent News & Updates
Shareholder Returns
| NNOX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.6% | 2.9% | 5.9% |
| 1Y | -58.5% | -14.9% | -10.2% |
Return vs Industry: NNOX underperformed the US Medical Equipment industry which returned -15.8% over the past year.
Return vs Market: NNOX underperformed the US Market which returned -15.1% over the past year.
Price Volatility
| NNOX volatility | |
|---|---|
| NNOX Average Weekly Movement | 13.2% |
| Medical Equipment Industry Average Movement | 10.5% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NNOX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: NNOX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 186 | Erez Meltzer | https://www.nanox.vision |
Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode.
Nano-X Imaging Fundamentals Summary
| NNOX fundamental statistics | |
|---|---|
| Market Cap | US$540.59m |
| Earnings (TTM) | -US$70.75m |
| Revenue (TTM) | US$3.11m |
173.7x
P/S Ratio-7.6x
P/E RatioIs NNOX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NNOX income statement (TTM) | |
|---|---|
| Revenue | US$3.11m |
| Cost of Revenue | US$6.54m |
| Gross Profit | -US$3.43m |
| Other Expenses | US$67.32m |
| Earnings | -US$70.75m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.36 |
| Gross Margin | -110.25% |
| Net Profit Margin | -2,273.36% |
| Debt/Equity Ratio | 1.4% |
How did NNOX perform over the long term?
See historical performance and comparisonValuation
Is Nano-X Imaging undervalued compared to its fair value and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
1.95x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NNOX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NNOX's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: NNOX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Medical Equipment industry average.
PE vs Market: NNOX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NNOX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NNOX is good value based on its Price-To-Book Ratio (2x) compared to the US Medical Equipment industry average (2.5x).
Future Growth
How is Nano-X Imaging forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score
5/6Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
68.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NNOX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: NNOX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NNOX's is expected to become profitable in the next 3 years.
Revenue vs Market: NNOX's revenue (95.1% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: NNOX's revenue (95.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NNOX's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Nano-X Imaging performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-47.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NNOX is currently unprofitable.
Growing Profit Margin: NNOX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NNOX is unprofitable, and losses have increased over the past 5 years at a rate of 47.9% per year.
Accelerating Growth: Unable to compare NNOX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NNOX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.1%).
Return on Equity
High ROE: NNOX has a negative Return on Equity (-25.54%), as it is currently unprofitable.
Financial Health
How is Nano-X Imaging's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: NNOX's short term assets ($78.1M) exceed its short term liabilities ($51.0M).
Long Term Liabilities: NNOX's short term assets ($78.1M) exceed its long term liabilities ($19.2M).
Debt to Equity History and Analysis
Debt Level: NNOX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if NNOX's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NNOX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NNOX has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 78.3% each year.
Dividend
What is Nano-X Imaging current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NNOX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NNOX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NNOX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NNOX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NNOX has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
0.3yrs
Average management tenure
CEO
Erez Meltzer (64 yo)
0.33
Tenure
Mr. Erez I. Meltzer is a Director at Turpaz Industries Ltd since May 18, 2021. He served as Chief Executive Officer at Nano-X Imaging Ltd. since January 2022 and also serves as its Director since December...
Leadership Team
Experienced Management: NNOX's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Board Members
Experienced Board: NNOX's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.4%.
Top Shareholders
Company Information
Nano-X Imaging Ltd.'s employee growth, exchange listings and data sources
Key Information
- Name: Nano-X Imaging Ltd.
- Ticker: NNOX
- Exchange: NasdaqGM
- Founded: 2011
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$540.595m
- Shares outstanding: 52.08m
- Website: https://www.nanox.vision
Number of Employees
Location
- Nano-X Imaging Ltd.
- Communications Center
- Neve Ilan
- 9085000
- Israel
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/27 00:00 |
| End of Day Share Price | 2022/05/27 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.